Treating SMA

CE / CME

What’s New in the Treatment of Spinal Muscular Atrophy

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurse Practitioners: 0.25 Nursing contact hours, includes 0.25 hour of pharmacotherapy credit

Released: April 18, 2023

Expiration: April 17, 2024

Vanessa Battista
Vanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN, FPCN
Julie Parsons
Julie Parsons, MD

Activity

Progress
1
Course Completed

In this episode, Dr. Parsons and Dr. Battista discuss current and emerging medical therapies for the treatment of spinal muscular atrophy (SMA). They review safety, efficacy, and monitoring parameters of current agents, as well as adjuct therapies in the medication pipeline. This high-level overview includes:

  • Review of FDA-approved medical therapies: nusinersen, onasemnogene abeparvovec-xioi, and risdiplam
  • Discussion of the safety, efficacy, and monitoring parameters for FDA approved medications, as well as adjuctive agents for medication therapy complications
  • Review of ongoing clinical trials on anti-myostatin medications and discussion of the role these agents would play if approved by the FDA